Therapy Areas: Central Nervous System
Seelos Therapeutics collaborates with Sean M Healey & AMG Center
3 October 2022 -

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a US-based clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced on Friday, that it is collaborating with the Sean M Healey & AMG Center for ALS (Amyotrophic Lateral Sclerosis).

The collaboration will involve an Expanded Access Program (EAP) that will be fully funded by a grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the ACT for ALS.

As part of the EAP, Seelos is planning to initially enrol 70 patients in a 24-week, open-label study to evaluate SLS-005 in persons with ALS along with its ongoing Phase II/III study on the HEALEY Platform. SLS-005, a low molecular weight disaccharide (0.342 kDa), is an investigational treatment and is not presently approved by any health authority for medicinal use.

Login
Username:

Password: